BRD3308 is an inhibitor of histone deacetylase 3 (HDAC3; Ki = 29 nM).1 It is selective for HDAC3 over HDAC1 and HDAC2 (Kis = 6,300 and 5,100 nM, respectively). BRD3308 (10 ?M) reduces cytokine-induced increases in apoptosis in rat INS-1E β cells. In vivo, BRD3308 (5 mg/kg) reduces plasma glucose levels in rats and increases plasma insulin levels in rats in a hyperglycemic clamp assay as a model of type 2 diabetes.2
1.An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell ProtectionACS Chem. Biol.11(2)363-374(2016) 2.Lundh, M., Galbo, T., Poulsen, S.S., et al.Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic ratsDiabetes Obes. Metab.17(7)703-707(2015)